Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
Current seasonal influenza vaccines mainly target a different, more abundant influenza surface protein called hemagglutinin (HA). However, because influenza vaccines offer varying and sometimes limited protection, scientists are exploring ways to improve vaccine effectiveness. The new research builds on previous studies of NA and was conducted by a team of scientists including investigators from the Centers of Excellence for Influenza Research and Surveillance (CEIRS)program, which is organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with either the 2009 H1N1 influenza virus or H3N2 influenza viruses. The volunteers were recruited for this study or had taken part in prior influenza research studies. The analyses indicate that influenza vaccines rarely induce NA-reactive antibodies, whereas natural influenza infection induces these types of antibodies at least as often as they induce HA-reactive antibodies. Additional studies in mice reinforced the human data, indicating that current influenza vaccines do not induce NA-reactive antibodies efficiently.
Additional laboratory experiments show that the NA-reactive antibodies induced during natural influenza infection are broadly reactive, meaning they could potentially protect against diverse strains of influenza. To test this theory, scientists isolated NA-reactive monoclonal antibodies from the H3N2 and H1N1 influenza patients (N2-reactive antibodies and N1-reactive antibodies, respectively). They administered 13 N2-reactive antibodies to mice and subsequently infected the mice with a different H3N2 virus strain. Eleven of the 13 N2-reactive antibodies partially or fully protected the mice. They also administered eight N1-reactive antibodies to mice and subsequently infected the mice with a similar H1N1 virus strain or an H5N1-like virus strain. Four of the eight antibodies completely protected the mice against both virus strains.
The authors note that the findings suggest that influenza vaccines should be optimized to better target NA for broad protection against diverse influenza strains. In this regard, NIAID is supporting research to characterize NA responses in infected and vaccinated individuals and to determine the mechanism of action of NA protection. NIAID also supports “NAction!” a CEIRS working group that identifies knowledge gaps in our understanding of NA and sets NA research priorities for improved influenza vaccines. These efforts contribute to NIAID’s larger plan to develop a universal influenza vaccine—a vaccine that can durably protect all age groups against multiple influenza virus strains.
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Is It COVID-19, Influenza A or B, or Something Else?on November 27, 2020 at 11:56 am
It’s flu season, but we’re also still in the midst of the COVID-19 pandemic. SARS-CoV-2 (COVID-19), influenza A or B (flu), and other respiratory infections can present with similar symptoms, such as ...
- Seasonal Influenza Vaccine Market 2020 Market Segment, Drivers, Trends, Forecast to 2025on November 25, 2020 at 2:07 pm
Global Seasonal Influenza Vaccine Market Research Report 2020 Cover Covid-19 Impact The study on the ‘Seasonal ...
- New study explains important cause of fatal influenzaon November 25, 2020 at 6:16 am
It is largely unknown why influenza infections lead to an increased risk of bacterial pneumonia. Researchers at Karolinska Institutet have now described important findings leading to so-called ...
- 1 Lesson From The Influenza Pandemic 100 Years Ago That Still Applies Todayon November 25, 2020 at 5:12 am
Dr. Brown shared lessons from the 1918 influenza pandemic that are still relevant today. Corinne Cardina: I'd like to get a little bit more general now, I want to hear about influenza. You, of course, ...
- Researchers describe important cause of fatal influenzaon November 25, 2020 at 4:52 am
It is largely unknown why influenza infections lead to an increased risk of bacterial pneumonia. Researchers at Karolinska Institutet in Sweden have now described important findings leading to ...
- Europe Influenza Treatment Market : Analysis and In-depth Study on Size Trends, Emerging Growth Factors and Regional Forecast to 2030on November 24, 2020 at 10:12 pm
Europe influenza treatment market accounted for $187.6 million in 2019 and will grow by 3.6% annually over 2020-2030 ...
- Developers roll out new COVID-19 test that also detects influenza and RSVon November 24, 2020 at 3:58 pm
Researchers at ARUP Laboratories are rolling out a new kind of nasal swab test that can detect three different respiratory illnesses with one exam.
- Roche: FDA Approves Influenza Drug Xofluza For Post-exposure Prophylaxison November 23, 2020 at 10:48 pm
(RTTNews) - Swiss drug maker Roche Group (RHHBY) announced Tuesday that the U.S. Food and Drug Administration has approved a supplemental New Drug Application or sNDA for Xofluza (baloxavir marboxil) ...
- FDA expands approved indication for influenza treatment to include post-exposure preventionon November 23, 2020 at 3:51 pm
Today, the U.S. Food and Drug Administration expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients 12 years of age and ...
via Bing News